Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2008-5-8
pubmed:abstractText
Community-acquired methicillin-resistant Staphylococcus aureus (MRSA) infection has become epidemic. Skin and soft-tissue infections (SSTIs) are the most frequent forms of the disease. Obtainment of culture specimens is important for documentation of the presence of MRSA and for susceptibility testing to guide therapy. Purulent lesions should be drained whenever possible. In areas where community-acquired MRSA isolates are prevalent, uncomplicated SSTI in healthy individuals may be treated empirically with clindamycin, trimethoprim-sulfamethoxazole, or long-acting tetracyclines, although specific data supporting the efficacy of these treatments are lacking. In healthy patients with small purulent lesions, drainage alone may be sufficient. In patients with complicated SSTI requiring hospitalization or intravenous therapy, vancomycin is the drug of choice because of the low cost, efficacy, and safety. Linezolid, daptomycin, and tigecycline are also effective, although published studies on the last 2 agents for the treatment of SSTI due to MRSA are more limited. Dalbavancin, telavancin, and ceftobiprole are investigational agents that may expand our therapeutic options for the treatment of SSTI caused by MRSA.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1537-6591
pubmed:author
pubmed:issnType
Electronic
pubmed:day
1
pubmed:volume
46 Suppl 5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S368-77
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus.
pubmed:affiliation
Duke Clinical Research Institute, Durham, North Carolina, USA. stryj001@mc.duke.edu
pubmed:publicationType
Journal Article, Review